• Q2 Sales: $479 million, down 17% year-over-year, including a $67 million impact from portfolio optimization.
• Adjusted EBITDA: $108 million, down 14% year-over-year, with a 60 basis point increase in margin to 22.5%.
• Adjusted EPS: $0.99 per share, down 22% from the prior year.
• Free Cash Flow: Negative $6 million for the quarter.
• Life Sciences Sales: $172 million, down 23% year-over-year, impacted by portfolio optimization.
• Life Sciences Adjusted EBITDA Margin: 32.6%, up 290 basis points year-over-year.
• Intermediates Sales: $37 million, down from $40 million in the prior year.
• Intermediates Adjusted EBITDA: $2 million, with a 5.4% margin.
• Personal Care Sales: $146 million, down 14% year-over-year.
• Personal Care Adjusted EBITDA Margin: 30.1%, up 350 basis points year-over-year.
• Specialty Additives Sales: $134 million, down 15% year-over-year.
• Specialty Additives Adjusted EBITDA Margin: 19.4%, up 220 basis points year-over-year.
• Share Repurchase: 1.5 million shares repurchased.
• Liquidity: Over $700 million available.
• Net Leverage: 2.8 times.
• Full Year Sales Outlook: $1.825 billion to $1.9 billion.
• Full Year Adjusted EBITDA Outlook: $400 million to $420 million.

• Warning! GuruFocus has detected 4 Warning Sign with IDCC.

Release Date: May 01, 2025

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Positive Points

• Ashland Inc (NYSE:ASH) completed its portfolio optimization, including the sale of the Avoca business, which is expected to enhance long-term profitability.
• Life Sciences and Personal Care segments achieved strong EBITDA margins above 30% for the first time simultaneously.
• The company is on track to exceed its fiscal year 2025 cost savings target, with significant progress in restructuring and manufacturing optimization.
• Ashland Inc (NYSE:ASH) has a strong financial foundation with over $700 million in liquidity and a manageable net leverage ratio of 2.8 times.
• The company is actively pursuing innovation and global expansion, with new facilities in Brazil and China to drive future growth.

Negative Points

• Q2 sales decreased by 17% year-over-year, impacted by portfolio optimization and lower organic sales volumes.
• Intermediates segment faced pricing pressures and reduced production due to a challenging demand environment.
• The company adjusted its fiscal year 2025 outlook due to increasing economic uncertainty and softer consumer demand.
• Specialty Additives experienced volume declines in China and competitive intensity in export markets, impacting overall performance.
• Free cash flow was negative $6 million in Q2, reflecting typical seasonality and ongoing inventory management challenges.

Q & A Highlights

Q: How has order volatility changed over the last couple of quarters, and what do customers need to see for more stable order patterns? A: Guillermo Novo, Ashland Inc's CEO, noted that the most significant volatility occurred in Q3 and Q4 of the previous year, particularly due to dynamics in China. Recently, things have stabilized, with volumes picking up and pricing aligning with full-year guidance. The current focus is on managing sentiment in certain markets, particularly in the US and Europe, where demand has been softer than expected.

Q: Regarding the $70 million of US-produced China sales, how much of the risk can be mitigated by the fourth quarter? A: Guillermo Novo explained that Ashland has inventory in China and is working with customers to mitigate risks. The company can manage short-term challenges, particularly with unique products like Klucel, which are difficult for customers to reformulate. While VP&D is more exposed, Ashland is exploring options to shift production and optimize its supply chain.

Q: How are tariffs impacting Ashland's supply chains in regions like Europe, Canada, and Mexico? A: Guillermo Novo stated that outside of China, the impact is minimal as most raw materials are sourced regionally. The company is monitoring Europe closely, as it is a significant manufacturing location. John Willis, CFO, added that Ashland maintains a lot of finished goods inventory in Europe, which would delay any tariff impact.

Q: Have you seen any slowing of competitive pressure in the Specialty Additives segment in China, and is there equilibrium in supply-demand? A: Guillermo Novo and Dago Caceres, General Manager of Specialty Additives, noted that China is stable at the bottom, with no further decline in volumes or prices. Europe is flattish, with a focus on quality and sustainability, while the US market is characterized by uncertainty. Other regions like India are growing, but pricing pressure continues.

Q: What are Ashland's cash flow expectations for the year, given the negative cash flow from operations in the first half? A: John Willis explained that cash flow will depend on several factors, including EBITDA performance, working capital, FX impacts, and restructuring costs. While there is uncertainty, free cash flow is expected to be in the range of $150 million to $200 million, assuming stability in these areas.

For the complete transcript of the earnings call, please refer to the full earnings call transcript.